In our BC TMA, 85% of the patients had ER+ tumors and our data pointed to distinct roles for LGR5 in ER+ vs. ER− BC, presenting as a favorable variable for ER+ patients but unfavorable for high grade ER− patients. This evidence concerns the gene LGR5 and breast cancer.